X0609 4 2026-06-01 0001088856 CORCEPT THERAPEUTICS INC CORT 0001678419 Mokari Atabak false C/O CORCEPT THERAPEUTICS INCORPORATED 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065 false true false false Chief Financial Officer true Common Stock 2026-06-01 4 M false 40000 19.26 A 55257 D Common Stock 2026-06-01 4 S false 40000 70.0001 D 15257 D Common Stock 2026-06-01 4 A false 634 70.44 A 15891 D Common Stock 2026-06-01 4 A false 634 0.00 A 16525 D Common Stock 2026-06-02 4 F false 395 70.44 D 16130 D Stock option (right to buy) 19.26 2026-06-01 4 M false 40000 0.00 D 2032-02-02 Common Stock 40000 60000 D Includes 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.00 to $70.01 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. The closing price on June 1, 2026 was used to calculate the withholding obligation. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Fully exercisable. The power of attorney under which this form was signed is on file with the Commission. /s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari 2026-06-03